HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials

Peer Reviewer Consultant/Advisory Board Speakers' Bureau/Honoraria Research Grant Fellowship Support Board Mbs/Stock Options/Partner Others Sharon Hunt, MD None None None None None None John Burnett, MD Chaire, Nile Therapeutics, Trevena, Bayer, Novartis, Merck, Anexon None None None Zumbro Discovery Intellectual property rights, Nile Therapeutics James R. Edgerton, MD AtriCure AtriCure None None None None Sana Al-Khatib, MD None None None None None None Anne Curtis, MD Bristol-Myers Squibb, Janssen Pharmaceuticals, Biosense Webster, Inc., Sanofi Aventis, St. Jude Medical, Daiichi Sankyo, Pfizer, Jones & Bartlett None Medtronic, Inc. None None None Valentin Fuster, MD, PhD None None None None None None David R. Holmes, Jr., MD None None None None None None Jodie L. Hurwitz, MD Biosense Webster, Inc. St. Jude Medical, Medtronic Inc., Boehringer Ingelheim None None None Heart Rhythm Society The Heart Hospital Baylor Plan, Medical City Hospital Gregory M. Marcus, MD None None Medtronic, Inc., Gilead SentreHeart None None None Simone Musco, MD None Bristol-Myers Squibb, Pfizer None None None None Patrick T. O'Gara, MD None None None None None Lantheus Medical Imaging National Institutes of Health Brian Olshansky, MD Boston Scientific Corp., Boehringer Ingelheim, Medtronic, Inc., BioControl Medical, Ltd., Sanofi Aventis, Amarin None None None None Sanofi Aventis, Boston Scientific, Amarin Marwan Refaat, MD None None None None None None Frederico Gentile, MD None None None None None None L. Samuel Wann, MD United Healthcare None None None None None Table A2 Peer Reviewer Disclosure Table 0 = $0; 1 = $10,001 to $25,001 to $50,001 to $100,001.